Technical
Flow Cytometry
Tissue/Protein
Molecular
Histopathology
We offer full range of histopathology services including specimen paraffin processing and embedding, tissue sectioning, and automated hematoxylin and eosin (H&E) and immunohistochemistry (IHC) staining. We construct tissue microarrays (TMA) used for IHC assay development, validation and control purposes. Additionally, we routinely perform digital imaging for H&E and IHC slides analyzed by light microscopy using automated high-throughput processes and can provide high-resolution images. Our team consists of highly trained and experienced histotechnologists. All aspects of histology are monitored throughout the process, ensuring that SOPs are maintained and work is performed according to specific study protocols.
Pathology
At Navigate BioPharma, our experienced board certified on site pathologists provide support for assay development/validation services as needed and provide clinical support for clinical trial testing across hematopathology and solid tumor indications.
Our surgical pathologists review H&E stained slides to confirm pathology diagnosis, assess region of interest (ROI) in each slide, which serves as a guiding map for lab technologists, scientist and imaging technicians to perform downstream activities such as macrodissection for DNA/RNA isolation for downstream genomic testing, TMA construction, FISH studies, etc. Our pathologists also assess and score tumor-related biomarker expressions by IHC and FIHC.
Our hematopathologists perform a variety of activities in support of diagnosis and clinical trial testing including: reviewing and scoring Wright-Giemsa stained peripheral blood and bone marrow aspirate smears, H&E and IHC stained slides of bone marrow core biopsy and tissue blocks; supporting and approving flow cytometric analysis for disease confirmation of leukemia, lymphoma and other hematologic malignancies; assessing MRD analysis in pre- and post-treatment samples for endpoint analysis in phase I-III clinical trials; and reviewing and approving FISH results for prognostic indicators and molecular results for leukemia/lymphoma-related gene mutations.